Videos
Cathy started smoking when she was about 12 years old. She describes two psilocybin sessions at Johns Hopkins decades later that led to her quitting entirely.
60 Minutes – Psychedelic Science
“60 Minutes” is on researchers experimenting with psychedelics to treat addiction, depression and anxiety.
Richard – Psilocybin Cancer Anxiety Study
Richard Cone, a professor of biophysics at Johns Hopkins, participated in a research study exploring the psychotherapeutic potential of psilocybin for cancer-related anxiety and depression.
Tony – Psilocybin Cancer Anxiety Study
Tony participated in an innovative research study at Johns Hopkins University exploring the psychotherapeutic potential of psilocybin for cancer-related anxiety.
NYU Psilocybin Study
Researchers Stephen Ross and Gabby Agin Liebes present “Psilocybin for Cancer Related Anxiety & Depression – NYU Trial” at the Psychedelic Science 2017 Conference in Oakland, CA.
Johns Hopkins Psilocybin Project
Dr. Roland Griffiths presents “Johns Hopkins Psilocybin Project – Implications for Spirituality & Therapeutics” at the Psychedelic Science 2017 Conference in Oakland, CA.
Q&A: Psychedelic Neuroscience
Heffter President Dr. David Nichols and Heffter researcher Dr. Franz Vollenweider hold a Q&A on psychedelic neuroscience at the Psychedelic Science 2017 Conference in Oakland, CA.
Psilocybin & Patient Reports of Increased Connection
Dr. Rosalind Watts presents “Psilocybin & Patient Reports of Increased Connection to Self, Others, and World” at the Psychedelic Science 2017 Conference in Oakland, CA.
Psychedelic Neuroscience LSD Gives Up a Secret
Heffter President and co-founder Dr. David Nichols presents “Psychedelic Neuroscience LSD Gives Up a Secret” at the Psychedelic Science 2017 Conference in Oakland, CA.
Estalyn – Psilocybin Study Participant
Estalyn Walcoff talks about her experience with psilocybin treatment at NYU for emotional distress from cancer.
Magic Mushrooms and the Healing Trip
Eddie Marritz, a cinematographer and photographer in remission from small-cell carcinoma, was a participant in N.Y.U.’s Psilocybin Cancer Anxiety Study.
Annie Levy – Psilocybin Study Participant
An interview with Annie Levy about her experience with psilocybin as part of the Harbor-UCLA trial with cancer patients who have anxiety.
Lauri Kershman, M.D.
Lauri Kershman, M.D. speaks at the Psychedelic Science 2013 conference about her experience as a participant in the Johns Hopkins Psilocybin & Cancer trial.
“The Substance” – Interview with Johns Hopkins Psilocybin Cancer Project Participant 1
An interview with Clark Martin Ph.D., from the film “The Substance.”
Dr. Martin participated in the Johns Hopkins Psilocybin & Cancer trial.
“The Substance” – Interview with Johns Hopkins Psilocybin Cancer Project Participant 2
An interview with Janeen Delaney
from the film “The Substance.”
Ms. Delaney participated in the Johns Hopkins Psilocybin & Cancer trial.
Sarah – UNM Alcohol Dependence Study
Sarah describes her experience of becoming sober from alcohol dependence with psilocybin treatment at the University of New Mexico. This is the first psychedelic treatment for alcohol dependence in about 50 years.
UNM Alcohol Dependence Study: Sarah – longer interview
An extended version of Sarah’s video interview of her two psilocybin sessions and the results she experienced.
TEDxMidAtlantic – Roland Griffiths
Roland Griffiths, Ph.D., is Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine. His principal research focus in both clinical and preclinical laboratories has been on the behavioral and subjective effects of mood-altering drugs.
Franz Vollenweider – Neuronal Networks
Vollenweider will present his work using state-of the-art neuroimaging tools to explore the brain activity patterns underlying the psychological dimensions of psychedelic-induced altered states of consciousness (ASC).
Neurobiology of Psychedelics: Implication for Mood Disorders – Franz Vollenweider
Recent advances in our understanding of the neurobiology of psychedelics such as lysergic acid diethylamide (LSD), psilocybin, and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders.
Psilocybin, Addiction, and End of Life – Stephen Ross
Stephen Ross, M.D., is Associate Professor of Psychiatry and Child & Adolescent Psychiatry at New York University School of Medicine and Associate Professor of Oral and Maxillofacial Pathology, Radiology, and Medicine at the NYU College of Dentistry.
The science of psilocybin and its use to relieve suffering
Leading psychopharmacologist Roland Griffiths discloses the ways that psychedelic drugs can be used to create spiritually meaningful, personally transformative experiences for all patients, especially the terminally ill.
60 Minutes – Psychedelic Science
“60 Minutes” is on researchers experimenting with psychedelics to treat addiction, depression and anxiety.
Richard – Psilocybin Cancer Anxiety Study
Richard Cone, a professor of biophysics at Johns Hopkins, participated in a research study exploring the psychotherapeutic potential of psilocybin for cancer-related anxiety and depression.
Tony – Psilocybin Cancer Anxiety Study
Tony participated in an innovative research study at Johns Hopkins University exploring the psychotherapeutic potential of psilocybin for cancer-related anxiety.
NYU Psilocybin Study
Researchers Stephen Ross and Gabby Agin Liebes present “Psilocybin for Cancer Related Anxiety & Depression – NYU Trial” at the Psychedelic Science 2017 Conference in Oakland, CA.
Psilocybin & Patient Reports of Increased Connection
Dr. Rosalind Watts presents “Psilocybin & Patient Reports of Increased Connection to Self, Others, and World” at the Psychedelic Science 2017 Conference in Oakland, CA.
Estalyn – Psilocybin Study Participant
Estalyn Walcoff talks about her experience with psilocybin treatment at NYU for emotional distress from cancer.
Magic Mushrooms and the Healing Trip
Eddie Marritz, a cinematographer and photographer in remission from small-cell carcinoma, was a participant in N.Y.U.’s Psilocybin Cancer Anxiety Study.
Annie Levy – Psilocybin Study Participant
An interview with Annie Levy about her experience with psilocybin as part of the Harbor-UCLA trial with cancer patients who have anxiety.
Lauri Kershman, M.D.
Lauri Kershman, M.D. speaks at the Psychedelic Science 2013 conference about her experience as a participant in the Johns Hopkins Psilocybin & Cancer trial.
“The Substance” – Interview with Johns Hopkins Psilocybin Cancer Project Participant 1
An interview with Clark Martin Ph.D., from the film “The Substance.”
Dr. Martin participated in the Johns Hopkins Psilocybin & Cancer trial.
“The Substance” – Interview with Johns Hopkins Psilocybin Cancer Project Participant 2
An interview with Janeen Delaney
from the film “The Substance.”
Ms. Delaney participated in the Johns Hopkins Psilocybin & Cancer trial.
Cathy – Psilocybin Smoking Cessation Study
Cathy started smoking when she was about 12 years old. She describes two psilocybin sessions at Johns Hopkins decades later that led to her quitting entirely.
UNM Alcohol Dependence Study: Sarah – longer interview
An extended version of Sarah’s video interview of her two psilocybin sessions and the results she experienced.
Sarah – UNM Alcohol Dependence Study
Sarah describes her experience of becoming sober from alcohol dependence with psilocybin treatment at the University of New Mexico. This is the first psychedelic treatment for alcohol dependence in about 50 years.
Psilocybin, Addiction, and End of Life – Stephen Ross
Stephen Ross, M.D., is Associate Professor of Psychiatry and Child & Adolescent Psychiatry at New York University School of Medicine and Associate Professor of Oral and Maxillofacial Pathology, Radiology, and Medicine at the NYU College of Dentistry.
Johns Hopkins Psilocybin Project
Dr. Roland Griffiths presents “Johns Hopkins Psilocybin Project – Implications for Spirituality & Therapeutics” at the Psychedelic Science 2017 Conference in Oakland, CA.
TEDxMidAtlantic – Roland Griffiths
Roland Griffiths, Ph.D., is Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine. His principal research focus in both clinical and preclinical laboratories has been on the behavioral and subjective effects of mood-altering drugs.
The science of psilocybin and its use to relieve suffering
Leading psychopharmacologist Roland Griffiths discloses the ways that psychedelic drugs can be used to create spiritually meaningful, personally transformative experiences for all patients, especially the terminally ill.
Q&A: Psychedelic Neuroscience
Heffter President Dr. David Nichols and Heffter researcher Dr. Franz Vollenweider hold a Q&A on psychedelic neuroscience at the Psychedelic Science 2017 Conference in Oakland, CA.
Psychedelic Neuroscience LSD Gives Up a Secret
Heffter President and co-founder Dr. David Nichols presents “Psychedelic Neuroscience LSD Gives Up a Secret” at the Psychedelic Science 2017 Conference in Oakland, CA.
Franz Vollenweider – Neuronal Networks
Vollenweider will present his work using state-of the-art neuroimaging tools to explore the brain activity patterns underlying the psychological dimensions of psychedelic-induced altered states of consciousness (ASC).
Neurobiology of Psychedelics: Implication for Mood Disorders – Franz Vollenweider
Recent advances in our understanding of the neurobiology of psychedelics such as lysergic acid diethylamide (LSD), psilocybin, and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders.